LEADER 04740nam 2200613z- 450 001 9910163538103321 005 20210211 035 $a(CKB)3710000001048138 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/49986 035 $a(oapen)doab49986 035 $a(EXLCZ)993710000001048138 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aImmunogenic Cell Death in Cancer: From Benchside Research to Bedside 210 $cFrontiers Media SA$d2016 215 $a1 online resource (145 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-838-3 330 $aClassically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated 'danger signaling' remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and 'danger signaling' has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of "immunogenic cell death" (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality. 517 $aImmunogenic Cell Death in Cancer 606 $aCell Death 606 $aApoptosis 606 $aMonitoring, Immunologic 606 $aGenes, Tumor Suppressor 606 $aImmunogenic Cell Death 606 $aNeoplasms 610 $aanti-tumor immunity 610 $aApoptosis 610 $acancer immunology 610 $acancer immunotherapy 610 $aCell Death 610 $aDAMPs 610 $adanger signals 610 $aimmunocontexture 610 $aimmunosurveillance 610 $anecroptosis 610 $apatient immunology 610 $aprognostic/predictive biomarker 615 2$aCell Death. 615 2$aApoptosis. 615 2$aMonitoring, Immunologic. 615 2$aGenes, Tumor Suppressor. 615 2$aImmunogenic Cell Death. 615 2$aNeoplasms. 700 $aAbhishek D. Garg$4auth$01331951 702 $aPatrizia Agostinis$4auth 906 $aBOOK 912 $a9910163538103321 996 $aImmunogenic Cell Death in Cancer: From Benchside Research to Bedside$93040695 997 $aUNINA LEADER 03142oam 2200709 c 450 001 9910163117803321 005 20260302090207.0 010 $a3-86496-939-5 010 $a3-86496-938-7 010 $a3-86496-937-9 024 3 $a9783864969386 035 $a(CKB)3710000001045568 035 $a(MiAaPQ)EBC4518500 035 $a(MiAaPQ)EBC6000476 035 $a(UVK Verlag)9783864969386 035 $a(Narr)9783864969386 035 $a(EXLCZ)993710000001045568 100 $a20260302d2016 uy 0 101 0 $ager 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aInternationales Finanzmanagement $eGrundlagen der internationalen Unternehmensfinanzierung /$fManfred Perlitz, Randolf Schrank, Kai Wiltinger 205 $a1st ed. 210 $aTübingen$cUVK Verlag$d2016 215 $a1 online resource (102 pages) $cillustrations 300 $a[1. Auflage] 311 08$a3-86764-599-X 320 $aIncludes bibliographical references and index. 330 $aTrotz des anhaltend niedrigen Zinsniveaus in der Weltwirtschaft hat die Bedeutung eines international ausgerichteten Finanzmanagement keinesfalls an Bedeutung verloren. Die zentrale Zielsetzung besteht in der Liquiditätssicherung und damit der Sicherung der Unternehmensexistenz. Aus diesem Grund müssen sich Finanzmanager in internationalen Unternehmen darüber Gedanken machen, wie sie Kapital und Zahlungsströme vor dem Hintergrund einer rendite- oder wertorientierten Unternehmenszielsetzung optimieren können. Der Autor zeigt verständlich die Grundlagen, Prozess und Instrumente des Internationalen Finanzmanagements auf. Mit den Themen Mergers & Acquisitions sowie der Private Equity Finanzierung spricht er auch zwei Sonderprobleme an, die in diesem Umfeld eine besondere Rolle spielen. Zur Veranschaulichung enthält der Band Praxisbeispiele und eine ausführliche Fallstudie. Das Buch richtet sich an Praktiker, die einen schnellen Einstieg in das internationale Finanzmanagement suchen sowie an Studierende, die ein praktisches Verständnis für das Thema erlangen möchten. 606 $aBWL 606 $aEigenfinanzierung 606 $aFinanzdisposition 606 $aFinanzmanagement 606 $aFremdfinanzierung 606 $aKapitalbeschaffung 606 $aLiquidität 606 $aLiquiditätssicherung 606 $aTochtergesellschaft 606 $aVertriebsgesellschaft 615 4$aBWL 615 4$aEigenfinanzierung 615 4$aFinanzdisposition 615 4$aFinanzmanagement 615 4$aFremdfinanzierung 615 4$aKapitalbeschaffung 615 4$aLiquidität 615 4$aLiquiditätssicherung 615 4$aTochtergesellschaft 615 4$aVertriebsgesellschaft 676 $a658.1599 700 $aPerlitz$b Manfred$4aut$01205388 702 $aSchrank$b Randolf$4aut 702 $aWiltinger$b Kai$4aut 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910163117803321 996 $aInternationales Finanzmanagement$92782226 997 $aUNINA